title: PI3K: A rational target for ovarian cancer therapy?
authors.affiliation: Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, 23298-0035, USA. pdent@vcu.edu
authors.forename: Paul
authors.initials: P
authors.lastname: Dent
authors.forename: Steven
authors.initials: S
authors.lastname: Grant
authors.forename: Paul B
authors.initials: PB
authors.lastname: Fisher
authors.forename: David T
authors.initials: DT
authors.lastname: Curiel
mesh_terms: D002470:Cell Survival; D004789:Enzyme Activation; D005260:Female; D006801:Humans; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics* / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D017978:Receptors, Growth Factor / Q000502:physiology; D015398:Signal Transduction
chemical_list: D017978:Receptors, Growth Factor; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase